Neurol. praxi. 2013;14(1):8-11

Paraneoplastic neurological syndromes - essential characteristics, classification, etiopathogenesis and diagnostics

doc.MUDr.Pavel Štourač, Ph.D.1, prof.MUDr.Zdeněk Ambler, DrSc.2
1 Neurologická klinika LF MU a FN Brno
2 Neurologická klinika LF UK a FN Plzeň

Paraneoplastic neurological syndromes (PNS) are a heterogeneous group of disorders and may affect any part of the nervous system, neuromuscular

junction and muscles. Evidence is increasing that most PNS are immune – mediated. The current concept is that the expression of

neuronal proteins by a tumor provokes an immune response against both the tumor and the nervous system. A patient produces tumor-directed

antibodies known as onconeural antibodies and because of antigenic identity, these onconeural antibodies attack components of the

nervous system as well. Based on the clinical syndrome, the type of antibody, and the presence or absence of cancer, patients are classified

as having a definite or possible PNS. Onconeural antibodies are classified either as well characterized with a strong cancer association or partially

characterized. Some other antibodies may occur in both cancer- and non-cancer-associated syndromes. Diagnosis of PNS is important

because it can lead to the early detection of the tumor. The symptoms of PNS occur in approximately two thirds of patients before the presence

of systemic cancer is known. Treatment of the tumor is the most effective step in controlling or at least stabilizing the neurological disorder.

Keywords: paraneoplastic syndrome – classical, definite, possible; onconeural antibodies

Published: March 1, 2013  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Štourač P, Ambler Z. Paraneoplastic neurological syndromes - essential characteristics, classification, etiopathogenesis and diagnostics. Neurol. praxi. 2013;14(1):8-11.
Download citation

References

  1. Antoine JC, Absi L, Honnorat J, Boulesteix JM, de Brouker T, Vial C, Butler M, De Camilli P, Michel D. Antiamphiphysin antibodies are associated with various paraneoplastic neurological syndromes and tumours. Arch Neurol 1999; 56: 172-177. Go to original source... Go to PubMed...
  2. Braik T, Evans AT, Telfer M, McDunn S. Paraneoplastic neurological syndromes: unusual presentations of cancer. A practical review. Am J Med Sci. 2010; 340: 301-308. Go to original source... Go to PubMed...
  3. Dalmau J, Rosenfeld MR. Update on paraneoplastic neurologic disorders. Commun Oncol 2010; 7: 219-224. Go to original source... Go to PubMed...
  4. Denny-Brown D. Primary sensory neuropathy with muscular changes associated with carcinoma. J Neurol Neurosurg Psychiatry. 1948; 11: 73-87. Go to original source... Go to PubMed...
  5. Gozzard P, Maddison P. Which antibody and which cancer in which paraneoplastic syndromes? Pract Neurol 2010; 10: 260-270. Go to original source... Go to PubMed...
  6. Graus F, Delattre JY, Antoine JC, Dalmau J, Giometto B, Grisold W, Honnorat J, Smitt PS, Vedeler Ch, Verschuuren JJGM, Vincent A, Voltz R. Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry 2004; 75: 1135-1140. Go to original source... Go to PubMed...
  7. Graus F, Keime-Guibert F, Re?e R, Benyahia B, Ribalta T, Ascaso C, Escaramis G, Delattre JY. Anti-Hu associated paraneoplastic encephalomyelitis: analysis of 200 patients. Brain 2001; 124: 1138-48. Go to original source... Go to PubMed...
  8. Greenfield JG. Subacute spinal cerebellar degeneration occurring in elderly patients. Brain. 1934; 57: 161-176. Go to original source...
  9. Hoffmann LA, Jarius S, Pellkofer HL, Schueller M, Krumbholz M, Koenig F, Johannis W, la Fougere C, Newman T, Vincent A, Voltz R. Anti-Ma and anti-Ta associated paraneoplastic neurological syndromes: 22 newly diagnosed patiens and review of previous cases. J Neurol Neurosurg Psychiatry 2008; 79: 767-773. Go to original source... Go to PubMed...
  10. Honnorat J, Antoine JC, Derrington E, Aguera M, Belin MF. Antibodies to a subpopulation of glial cells and a 66 kD developmental protein in patiens with paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry 1996; 61: 270-278. Go to original source... Go to PubMed...
  11. Honnorat J, Antoine JC. Paraneoplastic neurological syndromes. Orphanet J Rare Dis 2007; 2: 22. Go to original source... Go to PubMed...
  12. Maverakis E, Goodarzi H, Wehrli LN, Ono Y, Garcia MS. The etiology of paraneoplastic autoimmunity. Clinic Rev Allerg Immunol 2012; 42: 135-144. Go to original source... Go to PubMed...
  13. Pelosof LC, Gerber DE. Paraneoplastic syndromes: an approach to diagnosis and treatment. Mayo Clin Proc. 2010; 85: 838-854. Go to original source... Go to PubMed...
  14. Rees JH. Paraneoplastic syndromes: when to suspect, how to confirm, and how to manage. J Neurol Neurosurg Psychiatry 2004; 75(Suppl II): 43-50. Go to original source... Go to PubMed...
  15. Sutton IJ, Barnett MH, Watson JDG, Ell JJ, Dalmau J. Paraneoplastic brainstem encephalitis and anti-Ri antibodies. J Neurol 2002; 249: 1597-1598. Go to original source... Go to PubMed...
  16. Tampoia M, Zucano A, Antico A, Giometto B, Bonaguri C, Alessio MG, Radice A, Platzgummer S, Bizzaro N. Diagnostic accuracy of different immunological methods for the detection of antineuronal antibodies in paraneoplastic neurological syndromes. Immunol Invest 2010; 39: 186-195. Go to original source... Go to PubMed...
  17. Voltz R. Paraneoplastic neurological syndromes: an update on diagnosis, pathogenesis, and therapy. Lancet Neurol 2002; 1: 294-305. Go to original source... Go to PubMed...




Neurology for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.